Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations
Latest Information Update: 19 Aug 2022
At a glance
- Drugs Opicapone (Primary) ; Antiparkinsonians; Decarboxylase inhibitors; Entacapone; Levodopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms OPTIPARK; OPTIPARK_V1
- Sponsors Bial; BIAL - Portela C S.A.
- 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology
- 22 Sep 2021 Results assessing opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson's disease (PD) patients with motor fluctuations, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
- 22 Sep 2021 Results of post-hoc analysis assessing the influence of onset of motor fluctuation (OMF) on the response to opicapone (OPC) treatment in patients with Parkinson's disease (PD) treated in real-world conditions, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.